Holen Sie sich die Stockscreener-App
17.16
1.96%
0.35
Schlusskurs vom Vortag:
$16.81
Offen:
$16.66
24-Stunden-Volumen:
143.11K
Relative Volume:
0.14
Marktkapitalisierung:
$1.78B
Einnahmen:
$71.78M
Nettoeinkommen (Verlust:
$-295.28M
KGV:
-5.4309
EPS:
-3.1597
Netto-Cashflow:
$-271.85M
1W Leistung:
+3.94%
1M Leistung:
+10.50%
6M Leistung:
+39.80%
1J Leistung:
+52.08%
1-Tages-Spanne:
$16.50
$17.27
1-Wochen-Bereich:
$16.20
$17.49
52-Wochen-Spanne:
$8.195
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
17.18 | 1.74B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
426.25 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
709.03 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.26 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.67 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.01 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-11 | Eingeleitet | Jefferies | Buy |
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform |
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
(NRIX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Nurix Therapeutics CLO Christine Ring sells $90,406 in stock By Investing.com - Investing.com India
Nurix Therapeutics CLO Christine Ring sells $90,406 in stock - Investing.com
Nurix Therapeutics (NRIX) legal chief sells 5,394 shares in planned trade - Stock Titan
Issuer (NASDAQ: NRIX) reports proposed RSU sale by executive - Stock Titan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 2,388 Shares - MarketBeat
Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) Insider Sells 3,214 Shares of Stock - MarketBeat
Nurix therapeutics CSO Hansen sells $53,497 common stock - Investing.com UK
Nurix therapeutics CSO Hansen sells $53,497 common stock By Investing.com - Investing.com India
Nurix therapeutics CFO Hans van Houte sells $39,748 in shares By Investing.com - Investing.com India
Nurix Therapeutics CLO Christine Ring sells $53,497 in shares By Investing.com - Investing.com Canada
Nurix Therapeutics CLO Christine Ring sells $53,497 in shares - Investing.com
Nurix (NRIX) CFO nets shares after RSU vesting tax sale - Stock Titan
Tax-driven share sale and RSU vesting for Nurix (NRIX) - Stock Titan
Nurix (NRIX) CSO Hansen converts RSUs, sells 3,214 shares to cover taxes - Stock Titan
Pictet Asset Management Holding SA Acquires 1,487,060 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
California Biopharma Co. Uncovers Massive Oncology Breakthrough - Streetwise Reports
Nurix Therapeutics shares edge higher despite Q1 earnings miss - MSN
Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? - MSN
Institutional Investors Accumulate Nurix Therapeutics Stock on TPD Leadership - HarianBasis.co
Nurix Therapeutics Inc. (NRIX): Leadership in Targeted Protein Degradation Attracts Smart Money - Insider Monkey
NRIX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $32 - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy on Nurix stock, $32 target - Investing.com UK
H.C. Wainwright reiterates Buy on Nurix stock, $32 target By Investing.com - Investing.com Australia
Billionaire Joe Edelman’s 5 Stock Picks with Huge Upside Potential - Insider Monkey
Assessing Nurix Therapeutics (NRIX) Valuation After New AACR 2026 Oncology Data - Sahm
Redmile (NRIX) holds 10.7M shares — 9.9% including warrants - Stock Titan
Nurix Therapeutics (NRIX) Receives a Buy from Piper Sandler - The Globe and Mail
NRIX Price Today: Nurix Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Does Nurix Therapeutics (NRIX) have the potential to rally 85.84% as Wall Street analysts expect? - MSN
NRIX Reiterates by Needham -- Price Target Maintained at $26 - GuruFocus
Needham & Company LLC Reiterates Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
(NRIX) Risk Channels and Responsive Allocation - Stock Traders Daily
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 - The Manila Times
In preclinical brain metastasis model, Nurix drug lifted lifespan 142% - Stock Titan
Nurix presents preclinical oncology data at AACR meeting - Investing.com
Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight - GlobeNewswire Inc.
Analyst Firms Adjust Nurix Therapeutics Price Targets Following Financial Reports - HarianBasis.co
Nurix (NRIX) Stock: Smart Money Signals (-2.34%) 2026-04-20Professional Trade Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Wells Fargo Cuts PT on Nurix Therapeutics (NRIX) to $28 From $29 - Insider Monkey
Nurix Therapeutics (NRIX) Is Up 9.2% After Reporting Sharply Lower Q1 Revenue And Wider Loss - Sahm
5 Best Low Priced Biotech Stocks to Invest In - Insider Monkey
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
2.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):